ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
၇.၉၂ US$
၀.၀၀%
(၀.၀၀) 1D
၈.၀၅ US$
arrow_upward
+၁.၆၄% (+၀.၁၃)bedtimeAfter hours
Closed: မေ ၂၉, GMT-၄ ၁၆:၀၀:၀၁ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARCT...
Open
၇.၈၉ US$
High
၈.၀၅ US$
Low
၇.၇၉ US$
Mkt. cap
၂၂.၅၁ ကုဋေ
Avg. vol.
၄.၁၂ သိန်း
Volume
၄.၁၁ သိန်း
52-wk high
၂၄.၁၄ US$
52-wk low
၅.၈၆ US$
EPS
-၂.၈၂ US$
Beta
၂.၄၃
Shares outstanding
၂.၈၄ ကုဋေ
No. of employees
၁၀၉
Open
၇.၈၉ US$
High
၈.၀၅ US$
Low
၇.၇၉ US$
Mkt. cap
၂၂.၅၁ ကုဋေ
Avg. vol.
၄.၁၂ သိန်း
Volume
၄.၁၁ သိန်း
52-wk high
၂၄.၁၄ US$
52-wk low
၅.၈၆ US$
EPS
-၂.၈၂ US$
Beta
၂.၄၃
Shares outstanding
၂.၈၄ ကုဋေ
No. of employees
၁၀၉
News stories
From sources across the web
Stock Traders Daily
·
ပြီးခဲ့သည့် ၁ ရက်
(ARCT) Movement Within Algorithmic Entry Frameworks
The Legal Advocate
·
ပြီးခဲ့သည့် ၁ ပတ်
Arc Tx (ARCT) Stock Today: Drops -6.76%, Key Support at $6.61 2026-05-18 - {涓偂鍓爣棰榼
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc
AI content may include mistakes. Learn more